Clinical Trial Update: A Study to Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Like Tyrosine Kinase 3 (FLT3) Mutation

View source ↗

Summary

A completed clinical trial assessed the safety of Xospata (gilteritinib) in patients with relapsed or refractory acute myeloid leukemia harboring FLT3 mutations…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia with Flt3 Mutation

Drugs mentioned

• Xospata (gilteritinib)

Snippet

Sponsor: Astellas Pharma Korea, Inc. | Conditions: Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation | Status: COMPLETED